Medicare coverage of Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy for heart disease is putting even more pressure on employers to cover the pricey drug that some are finding unaffordable.
The Centers for Medicare & Medicaid Services announced March 22 that Wegovy is now approved for coverage in Part D plans for patients who have cardiovascular disease, likely expanding access to the drug by commercial plans, said Dr. Angela Fitch, president of the Obesity Medicine Association and chief medical officer of knownwell.
The expansion for treatment comes as employers have been weighing potential long-term savings from reduced cardiovascular and other ...